We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Jun 2020 - 09 Jun 2020
Virtual Venue
08 Jun 2020 - 11 Jun 2020
Virtual Venue

Molecular Characteristics of Leptomeningeal Melanoma Metastases Identified

By LabMedica International staff writers
Posted on 20 Jan 2020
Print article
Image: Histopathology of Leptomeningeal Melanoma Metastases: tumor cell clusters in the subarachnoid space in a brain biopsy (Photo courtesy of selbst).
Image: Histopathology of Leptomeningeal Melanoma Metastases: tumor cell clusters in the subarachnoid space in a brain biopsy (Photo courtesy of selbst).
Patients with advanced melanoma who develop metastases in the leptomeninges, the fluid filled membranes surrounding the brain and spinal cord, have an extremely poor prognosis. Most patients only survive for eight to 10 weeks after diagnosis.

Cancer development and progression are highly regulated by intricate interactions between cancer cells and the surrounding environment. Melanoma cells that invade and metastasize into the leptomeninges interact with the surrounding cerebrospinal fluid. One reason for the poor prognosis is that very little information is known about the molecular development of leptomeningeal melanoma metastases (LMM), making it difficult to develop effective therapies.

Molecular oncologists and their colleagues at the Moffitt Cancer Center (Tampa, FL, USA) collected a total of 45 serial cerebrospinal fluid (CSF) samples from 16 patients, eight of these with confirmed LMM. Of those with LMM, seven had poor survival (<4 months) and one was an extraordinary responder (still alive with survival >35 months). CSF samples were analyzed by mass spectrometry and incubated with melanoma cells that were subjected to RNA-Seq analysis. Functional assays were performed to validate the pathways identified.

The scientists reported that mass spectrometry analyses showed the CSF of most LMM patients to be enriched for pathways involved in innate immunity, protease-mediated damage, and insulin-like growth factor (IGF)-related signaling. All of these were anti-correlated in the extraordinary responder. The most commonly altered protein was Transforming growth factor beta 1 (TGF-β1). Interestingly, the one patient who had an extraordinary response to treatment displayed high levels of these proteins at baseline, but expression levels decreased as the patient responded to treatment.

RNA-Seq analysis showed CSF to induce PI3K/AKT, integrin, B-cell activation, S-phase entry, TNFR2, TGF-band oxidative stress responses in the melanoma cells. ELISA assays confirmed that TGF-β expression increased in the CSF of patients progressing with LMM. CSF from poorly responding patients conferred tolerance to BRAF inhibitor therapy in apoptosis assays. However, the protein expression patterns in the remaining LMM patients who had poor responses to treatment were high at baseline and remained high throughout treatment and disease progression.

The findings demonstrate that the CSF from LMM patients who did not respond to treatment promoted survival of melanoma cells, while the cerebrospinal fluid from the extraordinary responder did not promote survival. These observations suggest that molecules exist within the cerebrospinal fluid that can stimulate melanoma cell survival and prevent cell death.

The authors concluded that their analyses identified proteomic/transcriptional signatures in the CSF of patients who succumbed to LMM. They further showed that the CSF from LMM patients has the potential to modulate BRAF inhibitor responses and may contribute to drug resistance. The study was published on January 10, 2020 in the journal Clinical Cancer Research.

Related Links:
Moffitt Cancer Center


Print article

Channels

Microbiology

view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.